Diadema Partners
Diadema Partners reported 81 stocks worth $220M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (11.4%), COGT (9.3%) and ABVX (8.1%). Compared with Q2 2026, the fund opened new positions in BBIO, REPL and LQDA, added to COGT, ABVX and VRDN, trimmed UTHR, BMRN and RVMD and sold out of AMGN, NVO and RLAY.
Latest filing: what Diadema Partners did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() UTHR United Therapeutics Corp Del | $25M | 11.4% | 46K | −6,767 (−13%) | 4 of 8 | |
| 2 | ![]() COGT Cogent Biosciences Inc | $20.6M | 9.3% | 642K | +148K (+30%) | 8 of 8 | |
| 3 | ![]() ABVX Abivax SA | $17.7M | 8.1% | 178K | +15K (+9%) | 5 of 8 | |
| 4 | ![]() BMRN Biomarin Pharmaceutical Inc | $15.3M | 7.0% | 255K | −57K (−18%) | 7 of 8 | |
| 5 | ![]() RVMD Revolution Medicines Inc | $14.4M | 6.5% | 70K | −69K (−50%) | 6 of 8 | |
| 6 | ![]() VKTX Viking Therapeutics Inc | $14.1M | 6.4% | 433K | −8,642 (−2%) | 7 of 8 | |
| 7 | ![]() BBIO Bridgebio Pharma Inc | $6.8M | 3.1% | 104K | New position | 3 of 8 | |
| 8 | ![]() IMCR Immunocore Hldgs PLC | $6.7M | 3.0% | 222K | −33K (−13%) | 7 of 8 | |
| 9 | ![]() FDMT 4D Molecular Therapeutics in | $6M | 2.7% | 421K | −150K (−26%) | 2 of 8 | |
| 10 | ![]() VRDN Viridian Therapeutics Inc | $5.3M | 2.4% | 257K | +157K (+157%) | 6 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() AMGN Amgen Inc | $37.2M | 103K |
![]() NVO Novo-Nordisk A S F | $4.8M | 100K |
![]() RLAY Relay Therapeutics Inc | $4.3M | 231K |
![]() ZYME Zymeworks Inc | $3.7M | 142K |
![]() BIOA Bioage Labs Inc | $3.6M | 146K |
🔒 Free account: see all 30.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() VKTX Viking Therapeutics Inc | Put | $44.4M | 1.4M | +1,011,400 |
![]() BMY Bristol Myers Squibb Co | Call | $37.4M | 600K | 0 |
![]() VKTX Viking Therapeutics Inc | Call | $37.1M | 1.1M | −81,400 |
![]() KOD Kodiak Sciences Inc | Put | $28.2M | 297K | +150,100 |
![]() UTHR United Therapeutics Corp Del | Call | $25.7M | 48K | +47,500 |
🔒 Free account: see all 20.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Diadema Partners 13F FAQ
What does Diadema Partners own?
Diadema Partners reported 81 stocks worth $220M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (11.4%), COGT (9.3%) and ABVX (8.1%). The table above lists every position in the filing (the top 10 without an account).
What did Diadema Partners buy and sell in Q3 2026?
Compared with Q2 2026: 35 new positions, 16 added to, 26 trimmed and 31 sold out. New positions include BBIO, REPL and LQDA. It sold all of AMGN, NVO and RLAY.
When will Diadema Partners file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Diadema Partners's portfolio worth?
The Q3 2026 filing reports $220M in US stocks ($731M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.
























